| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OZEMPIC | 209637 | 001 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 2MG/1.5ML (1.34MG/ML) | Yes | No | 2017/12/05 | 2017/12/05 | NOVO | Discontinued |
| OZEMPIC | 209637 | 002 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 4MG/3ML (1.34MG/ML) | Yes | Yes | 2017/12/05 | 2019/04/09 | NOVO | Prescription |
| OZEMPIC | 209637 | 003 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 8MG/3ML (2.68MG/ML) | Yes | Yes | 2017/12/05 | 2022/03/28 | NOVO | Prescription |
| OZEMPIC | 209637 | 004 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | Yes | Yes | 2017/12/05 | 2022/10/06 | NOVO | Prescription |
| OZEMPIC | 209637 | 005 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 0.25MG/0.5ML (0.25MG/0.5ML) | Yes | Yes | 2017/12/05 | 2026/05/05 | NOVO | Prescription |
| OZEMPIC | 209637 | 006 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 0.5MG/0.5ML (0.5MG/0.5ML) | Yes | Yes | 2017/12/05 | 2026/05/05 | NOVO | Prescription |
| OZEMPIC | 209637 | 007 | NDA | SEMAGLUTIDE | SOLUTION;SUBCUTANEOUS | 1MG/0.5ML (1MG/0.5ML) | Yes | Yes | 2017/12/05 | 2026/05/05 | NOVO | Prescription |
| OZEMPIC | 213051 | 004 | NDA | SEMAGLUTIDE | TABLET;ORAL | 1.5MG | Yes | Yes | 2019/09/20 | 2024/12/09 | NOVO | Prescription |
| OZEMPIC | 213051 | 005 | NDA | SEMAGLUTIDE | TABLET;ORAL | 4MG | Yes | Yes | 2019/09/20 | 2024/12/09 | NOVO | Prescription |
| OZEMPIC | 213051 | 006 | NDA | SEMAGLUTIDE | TABLET;ORAL | 9MG | Yes | Yes | 2019/09/20 | 2024/12/09 | NOVO | Prescription |